ClinicalTrials.gg
Active, not recruitingNCT07482267Polytrauma ICUUpdated Mar 19, 2026

Evaluation of Patients Suffering From Polytrauma Admitted to the ICU

An observational study in Polytrauma Patients, sponsored by Jessa Hospital. Active, not recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Jessa Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
417
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to assess the number of polytrauma patients admitted to the Intensive Care Unit. In addition, we aim to describe their clinical characteristics, therapeutic management, and clinical outcomes.

Read the detailed description

Trauma constitutes a major contributor to global mortality and long-term physical disability. The principal causes of traumatic injury include road traffic accidents, falls, drowning, burns, poisoning, interpersonal violence, and acts of war. Collectively, these causes account for approximately 9% of global deaths.

Within the broader population of trauma patients, polytrauma patients represent a distinct and clinically significant subgroup, accounting for approximately 25% of trauma-related hospital admissions. Polytrauma is not merely defined as the coexistence of multiple injuries, but rather as a complex clinical condition characterized by a high risk of complications and progressive physiological deterioration. In the early post-traumatic phase, patients may develop severe hemorrhage, hemorrhagic shock, respiratory compromise, or traumatic brain injury. In the subsequent phase, systemic inflammatory response syndrome, sepsis, and multiple organ dysfunction syndrome may occur.

Advances in injury prevention strategies and improvements in trauma care have led to increased survival during the early stages following injury. As a result, a growing number of polytrauma patients require admission to the Intensive Care Unit (ICU), underscoring the need to optimize critical care delivery in this population. The provision of high-quality, evidence-based care depends on the systematic collection and analysis of comprehensive clinical data to facilitate continuous improvement in treatment strategies and outcomes.

02

Conditions studied

  • Polytrauma Patients

Browse trials for

Keywords

  • Polytrauma
  • Intensive Care Unit
03

In context

Multiple Trauma

139 studies on the registry are indexed under Multiple Trauma; 32 are open to participants now.

This study's planned enrollment of 417 is above the median of 200 across 84 observational studies indexed under Multiple Trauma.

Browse Multiple Trauma studies →

Lead sponsor

Jessa Hospital is the lead sponsor of 85 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients with a polytrauma admitted to the ICU between 01/01/2020 and 31/12/2025

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients with a polytrauma admitted to the ICU between 01/01/2020 and 31/12/2025

Exclusion criteria

Exclusion Criteria:

  • Younger than 18 years of age
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
417 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Mortality

    All patients with a polytrauma admitted to the ICU between 01/01/2020 and 31/12/2025

    Time frame: through study completion, an average of 1 year.

Secondary outcomes

  1. Length of stay

    The length of stay at ICU and hospital of all patients with a polytrauma admitted to the ICU between 01/01/2020 and 31/12/2025

    Time frame: through study completion, an average of 1 year.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2026
First posted
Mar 19, 2026
StartActual
Apr 10, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07482267
Lead sponsor
Jessa Hospital
Responsible party
Stessel Björn (Prof, Dr, Jessa Hospital) — Principal investigator
First posted
Mar 19, 2026
Start date
Apr 10, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion